PM AI Stock Analysis – Buy, Hold, or Avoid?
Philip Morris International Inc. (PM)
Fundamentals
Philip Morris International (PM) demonstrates resilient financial health and steady earnings growth driven by strong operational efficiencies and a consistent product portfolio. Recent quarters show solid revenue and EPS beats against estimates, supported by margin expansion and stable profitability metrics, positioning the company well within the tobacco sector despite regulatory challenges.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
10.37% YoY
Q2 2026
Net Income
-7.31% YoY
Q2 2026
Net Margin
Q2 2026
Growth Metrics
Revenue Growth YoY
Latest Quarter: Q2 2026
Net Income Growth YoY
Latest Quarter: Q2 2026
Revenue Per Share Growth YoY
Latest Quarter: Q2 2026
EPS Growth YoY
Latest Quarter: Q2 2026
Book Value Per Share Growth YoY
Latest Quarter: Q2 2026
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11.2B | 10.1B | 10.4B | 10.8B | 10.1B | 9.3B | 9.7B | 9.9B |
| Revenue Growth YoY | +10.37% | +9.09% | +6.76% | +9.42% | +7.10% | +5.78% | +7.28% | +8.42% |
| Net Income | 2.8B | 2.4B | 2.1B | 3.5B | 3.0B | 2.7B | -579.0M | 3.1B |
| Net Income Growth YoY | -7.31% | -9.37% | +469.78% | +12.85% | +26.31% | +25.23% | -126.37% | +50.05% |
| EPS | $1.80 | $1.56 | $1.37 | $2.23 | $1.95 | $1.72 | -$0.37 | $1.98 |
| EPS Growth YoY | -7.69% | -9.30% | +470.27% | +12.63% | +26.62% | +24.64% | -126.24% | +50.00% |
Profitability Metrics
Technical Analysis
Philip Morris International (PM) is currently in a strong medium-to-long-term uptrend characterized by price action above key moving averages and a golden cross confirming bullish momentum. However, recent short-term price behavior indicates a pullback or consolidation phase with bearish signals on daily MACD and below 20-day/50-day moving averages. The longer-term weekly indicators remain bullish, suggesting a healthy underlying trend despite short-term weakness.
No extreme reading
Price in uptrend
Trend developing
50 above 200 - bullish
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
Philip Morris International (PM) demonstrates resilient financial health and steady earnings growth driven by strong operational efficiencies and a consistent product portfolio. Recent quarters show solid revenue and EPS beats against estimates, supported by margin expansion and stable profitability metrics, positioning the company well within the tobacco sector despite regulatory challenges.
Valuation
Philip Morris International (PM) is viewed as moderately premium-priced relative to its industry peers, driven by strong operational margins, robust smoke-free product growth, and stable revenue expansion. Current market valuation reflects optimism around the company's transition to smoke-free products despite some valuation multiples appearing elevated compared to traditional tobacco sector averages.
Valuation Metrics
Price to Earnings
TTM
Price to Sales
TTM
Price to Book
TTM
Enterprise Value to EBITDA
TTM
Enterprise Value to Revenue
TTM
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Price to Earnings | 25.13 | 26.50 | 29.27 | 18.18 | 23.35 | 23.07 | -81.32 | 15.33 |
| Price to Sales | 25.26 | 25.47 | 24.10 | 23.29 | 27.97 | 26.52 | 19.27 | 19.05 |
| Price to Book | -32.94 | -27.85 | -24.99 | -23.14 | -23.70 | -22.63 | -15.92 | -19.47 |
| Enterprise Value to EBITDA | 71.85 | 69.17 | 65.18 | 62.81 | 78.96 | 72.73 | 52.65 | 56.50 |
| Enterprise Value to Revenue | 29.11 | 30.05 | 28.34 | 27.53 | 32.63 | 31.37 | 23.54 | 23.58 |
Sentiment & Analyst Ratings
Philip Morris International (PM) is experiencing largely positive market sentiment driven by robust second-quarter earnings, strategic expansion in smoke-free products, and favorable regulatory developments such as FDA authorization for ZYN nicotine pouches. Despite a premium valuation and some margin headwinds, the consensus among analysts and retail investors remains bullish, supported by recent leadership changes and operational investments. Overall, the stock is demonstrating strong momentum with a positive outlook for continued growth in smoke-free product revenue streams.
Analyst Recommendations
No analyst recommendations available.
Risk Assessment
Philip Morris International (PM) displays a moderately leveraged balance sheet with a heavy reliance on long-term debt supported by strong interest coverage, reflecting manageable financial risk despite liquidity constraints. Regulatory pressures, particularly around flavored nicotine products and evolving tobacco policies in the EU and U.S., create material business risks alongside intensifying competition in the reduced-risk product segment. From an investor standpoint, these factors suggest a moderate risk profile with challenges balanced against PM's solid market position and ongoing transformation efforts.
Liquidity & Solvency
Frequently Asked Questions about PM
AI Answers: Common Questions About PM
Get AI-powered answers to the questions investors ask most about Philip Morris International Inc.
Yes, PM is a good buy for medium and long-term investors given its 18% revenue growth, 17% EPS growth, and strong margin expansion to 68% gross margin. The stock trades at a P/E of 24.4, reflecting justified premium valuation supported by growth in smoke-free products.
Selling is not recommended currently as fundamentals and sentiment remain strong. Short-term traders may consider holding during the current technical pullback near $170-$175 support levels before potential upside continuation.
Key risks include regulatory scrutiny on tobacco and nicotine products, litigation exposure, currency fluctuations, and potential declines in traditional cigarette volumes. Liquidity constraints with a current ratio below 1.0 also pose short-term risks.
Analyst price targets average around $205-$210, supported by strong earnings growth and margin sustainability. Technical resistance near $190-$191 is a near-term hurdle before reaching these targets.
PM is fairly valued with a P/E of 24.4 and elevated EV/EBITDA multiples reflecting growth expectations. The premium is justified by above-industry revenue growth (~10% annually) and expanding smoke-free product contributions.
Fundamentals are robust with steady revenue growth from $9.5B to $11.2B in the latest quarter, EPS growth from $1.54 to $1.80, and margin expansion to 68% gross margin and 40% operating margin, driven by operational efficiencies and product innovation.
The long-term technical trend is bullish with price above major moving averages and a golden cross. Short-term momentum is weak with a pullback and bearish daily MACD, suggesting consolidation near $170-$175 support before potential resumption of uptrend.
Key catalysts include continued earnings beats, FDA approvals for smoke-free products like ZYN, expansion of manufacturing capacity, and leadership appointments focused on growth and innovation.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.